Biomarkers in Idiopathic Juvenile Arthritis

Idiopathic Juvenile Arthritis Clinical Trial

Official title:

Usefulness of Protoarray®Microarray for Identifying Biomarkers in Idiopathic Juvenile Arthritis Antinuclear Antibodies Positive.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02343770
• Other study ID #: 9355
• Status: Recruiting
• Phase: N/A
• First received: January 7, 2015
• Last updated: September 4, 2015
• Start date: June 2015
• Est. completion date: December 2016

Study information

• Verified date: September 2015
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de sant
• Study type: Interventional

Clinical Trial Summary

Juvenile idiopathic arthritis (JIA) is the most common form of arthritis in children. The etiology is unknown. Several types of arthritis fall under the JIA heading. Oligoarticular JIA with antinuclear antibodies affects about half of all children. There 's no specific markers. Our purpose is to identify new markers in this pathology. The ProtoArray®Human Protein Microarray allows rapid and efficient detection of protein interaction using a suitable protein or small molecule probe. The investigators hope so detect novel potential autoantigen biomarkers specific in JIA.

Description:

We select 10 patients with inclusion criteria and 10 controls. We analyse their blood sample (5ml). The ProtoArray® Microarray allows to detect novel protein-protein interactions, to rapidly perform serum profiling using a sensitive method to detect potential autoantigen biomarkers. The ProtoArray® Human Protein Microarray is a high-density protein microarray containing thousands of purified human proteins for protein interaction screening.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 2 Years to 16 Years

Eligibility

Inclusion Criteria for experimental group :

• child age from 2 to 16 years

• Oligoarticular JIA with antinuclear antibodies

• with or without uveitis

Exclusion criteria for experimental group :

• immunosuppressive and biological therapy

Inclusion Criteria for control group :

• child age from 2 to 16 years

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Juvenile
• Idiopathic Juvenile Arthritis

Intervention

Other:
• blood sample for identifying biomarkers

Locations

Country	Name	City	State
France	Cardiology paediatric consultation, Arnaud de Villeneuve Hospital	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	identification of specific autoantigen biomarkers	Identify blood sampling biomarkers of juvenile idiopathic arthritis	1 day	No